drugset / Trial / NCT06363994
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Compare the efficacy and safety of Orelabrutinib plus bendamustine+ rituximab versus bendamustine + rituximab in previously untreated patients with mantle cell lymphoma (MCL)
Timeline
- Start
- 2024-05-29
- Primary completion
- 2031-06-25
- Completion
- 2032-06-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Orelabrutinib | Small molecule | — | Oral |
| Comparator | Bendamustine | Small molecule | — | Other |
| Comparator | Rituximab | Monoclonal antibody | — | Other |